CASI Pharmaceuticals Inc., a biopharmaceutical company focused on cancer therapies for the global market with a commercial focus on China, has introduced Zevalin at hospitals in Hong Kong to patients with indicated non-Hodgkin’s lymphoma (NHL), including at Hong Kong Sanatorium & Hospital. The drug will be supplied by CASI and its local partner, Global Medical Solutions Hong Kong Limited. Zevalin (ibritumomab tiuxetan) is a FDA-approved product indicated for the treatment of patient...